Want to see INM full AI Analyst Report?
INM Stock Chart & Stats
$1.44
-$0.34(-7.10%)
At close: 4:00 PM EST
$1.44
-$0.34(-7.10%)
Day’s Range― - ―
52-Week Range$0.58 - $2.33
Previous CloseN/A
Volume49.03K
Average Volume (3M)52.24K
Market Cap
$7.25M
Enterprise Value$4.54M
Total Cash (Recent Filing)$2.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.78
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.48
Shares Outstanding5,493,735
10 Day Avg. Volume26,204
30 Day Avg. Volume52,239
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.00
Price to Sales (P/S)0.00203
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit0.01
Enterprise Value/Ebitda-0.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage, including zero reported total debt in 2026, gives the company greater financial flexibility than a highly indebted biotech. This reduces mandatory financing pressure and leaves more room to pursue research, transactions, or other strategic priorities.
Merger Financing And RunwayThe planned financing substantially strengthens the prospective combined company’s funding base and is expected to extend runway into 2029. That supports Phase 2a migraine-program readouts and broader pipeline development without relying immediately on repeated capital raises.
Strategic RepositioningThe proposed Mentari transaction could reposition InMed from a small cannabinoid-focused developer into a larger migraine-focused biotechnology platform. A clearer therapeutic focus and advancing clinical programs may improve strategic coherence and support future development scale.
Bears Say
Persistent Net LossesPersistent and substantial net losses show that the company has not yet established a profitable operating model. The very large 2026 loss weakens retained value and means future progress remains dependent on successful development, financing, or strategic execution.
Severe Cash BurnConsistently negative operating cash flow indicates the existing business does not fund itself, while the sharp 2026 deterioration increases sustainability risk. Continued cash consumption can force additional financing and may dilute stakeholders before products generate meaningful support.
Unstable Revenue And MarginsRevenue performance is highly inconsistent, and the 2026 step-change occurred alongside a lower gross margin and much larger loss. This combination makes the reported expansion difficult to view as durable operating improvement and limits confidence in future earnings quality.
InMed Pharmaceuticals News
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $0.57 and its highest was $2.33 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $7.25M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is Nov 06, 2026 which is in 18 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on Sep 09, 2026. The company reported -$1.434 earnings per share for the quarter.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 5,493,735 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$1.434 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Technical Analysis
Ownership Overview
39.32% Insiders
46.09% Other Institutional Investors
14.58% Public Companies and
Individual Investors